Professor Marc Feldmann Joins Trillium Therapeutics' Scientific Advisory Board

    TORONTO, June 8 /PRNewswire/ - Trillium Therapeutics Inc. (TTI) today
 announced that Dr. Marc Feldmann, a Professor at Imperial College London and
 Head of the Kennedy Institute of Rheumatology Division, has agreed to join the
 company's Scientific Advisory Board (SAB). Dr. Feldmann is welcomed to the
 board by fellow members Drs. Mohamed Sayegh, Vijay Kuchroo, Brian Barber and
 Gary Levy.
     "Marc Feldmann is a pioneer in cytokine research and his work in the TNF
 field is benefiting an ever increasing number of patients with autoimmune
 disorders", commented Dr. Niclas Stiernholm, TTI's Chief Executive Officer.
 "His experience and knowledge will provide us with an invaluable resource as
 we advance both our CD200 development candidate and our new cytokine
 antagonist program towards the clinic."
     Dr. Marc Feldmann, Head of Kennedy Institute of Rheumatology Division at
 the Imperial College London, is a leader in the field of TNF research and his
 work has paved the way for today's blockbuster TNF-blocking drugs, which are
 now used in a variety of autoimmune disorders. He has authored over 600
 scientific articles, has written and edited several books and serves on the
 editorial boards of a variety of scientific journals. Dr. Feldmann is the
 recipient of many awards, including the 2000 Crafoord Prize of the Royal
 Swedish Academy and 2003 Albert Lasker Clinical Research Award. He is an
 inventor on numerous patents and is the founder of the 2001 start-up company,
 Synovis.
     Trillium Therapeutics Inc. is a privately held Research and Development
 company that specializes in the development of innovative therapies that
 restore balance to the immune system in conditions associated with aberrant
 and harmful immune responses. These include autoimmune and inflammatory
 disorders, graft rejection, cancer and viral hepatitis. The Company identifies
 therapeutic candidates with promising preclinical profiles and advances these
 into clinical testing, with the primary objective of demonstrating safety and
 efficacy in humans. TTI currently has three development programs, one based on
 the CD200 immunoregulatory protein and its receptor, a second targeting the
 novel pro-thrombinase Fgl2, and a third that focuses on cytokine receptor
 antagonists. TTI has a broad network of external R&D collaborations, including
 several with major pharmaceutical and biotechnology companies.
 
 

SOURCE  Trillium Therapeutics Inc.